Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12-jo, Nishi-6-chome, Kita-ku, Sapporo 060-0812, Japan.
Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan.
J Pharm Biomed Anal. 2019 May 10;168:83-93. doi: 10.1016/j.jpba.2019.02.011. Epub 2019 Feb 13.
Breastfeeding is strongly encouraged for infant and maternal health. Benzodiazepines (BZDs) are widely prescribed drugs for symptoms, such as anxiety and insomnia, which many women could experience during the postpartum period. However, limited information is currently available to evaluate the transfer of different BZDs into breastmilk. In order to assess the proprieties of this medication during breastfeeding, robust and sensitive analytical methods to quantify BZDs are required. For this purpose, we developed a method for quantification of BZDs, including alprazolam, bromazepam, clonazepam, clotiazepam, etizolam, flunitrazepam, lorazepam, and CM7116 (a metabolite of ethyl loflazepate), in human breastmilk and plasma using liquid chromatography/tandem mass spectrometry (LC/MS/MS). Sample preparation was performed by a simple liquid-liquid extraction (LLE) with ethyl acetate. For sample preparation of CM7116, the pretreatment process to completely obtain the metabolite was added before the LLE step. The BZDs were separated by a C column using a gradient elution of acetonitrile in aqueous ammonium acetate solution, and were detected in the positive ion electrospray mode with multiple reaction monitoring (MRM). Lower limits of quantification (LLOQs) in breastmilk ranged from 0.25 to 0.5 ng/mL, and those in plasma ranged from 0.5 to 1.0 ng/mL. The intra-day and inter-day precision, and accuracy of data were assessed and found to be acceptable. The developed method was successfully applied to measure the concentration of alprazolam in breastmilk and plasma, which were donated by a lactating woman who had been regularly treated with alprazolam. Milk to plasma (M/P) ratios were calculated as 0.52 (before oral administration) and 0.49 (2 h after administration) 3 days after delivery. The M/P ratio 1 month after delivery was calculated as 0.41 (2 h after administration). We estimated that the relative infant dose (RID) values of alprazolam ranged from 3.11 to 4.61%.
母乳喂养对母婴健康有强烈的促进作用。苯二氮䓬类药物(BZDs)被广泛用于治疗焦虑和失眠等症状,许多女性在产后期间可能会经历这些症状。然而,目前可获得的信息有限,无法评估不同的 BZDs 转移到母乳中的情况。为了评估这种药物在母乳喂养期间的适用性,需要使用强大且敏感的分析方法来定量 BZDs。为此,我们开发了一种使用液相色谱/串联质谱法(LC/MS/MS)定量人乳和血浆中 BZDs 的方法,包括阿普唑仑、溴西泮、氯硝西泮、氯唑沙宗、依替唑仑、氟硝西泮、劳拉西泮和 CM7116(乙基亚硝戊酯的代谢物)。样品制备通过乙酸乙酯的简单液液萃取(LLE)进行。对于 CM7116 的样品制备,在 LLE 步骤之前添加了完全获得代谢物的预处理过程。BZDs 在 C 柱上使用乙腈在水溶液中的梯度洗脱进行分离,并以正离子电喷雾模式进行多反应监测(MRM)检测。乳中定量下限(LLOQ)范围为 0.25-0.5ng/mL,血浆中定量下限(LLOQ)范围为 0.5-1.0ng/mL。评估了日内和日间精密度和数据准确性,结果均符合要求。该方法成功应用于测量一位定期接受阿普唑仑治疗的哺乳期妇女的母乳和血浆中阿普唑仑的浓度。分娩后 3 天,乳汁与血浆(M/P)比值分别为 0.52(口服前)和 0.49(给药后 2 小时)。分娩后 1 个月的 M/P 比值计算为 0.41(给药后 2 小时)。我们估计阿普唑仑的相对婴儿剂量(RID)值范围为 3.11-4.61%。